ArticlePloS one2013
A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis.Molecules (Basel, Switzerland) · 2022Review
- Joint Damage and Neuropathic Pain in Rats Treated With Lysophosphatidic Acid.Frontiers in immunology · 2022Article
- Design and Development of Autotaxin Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.International journal of molecular sciences · 2020Article
- Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney.The Journal of clinical investigation · 2020Article
- Rapid Entry into Biologically Relevant α,α-Difluoroalkylphosphonates Bearing Allyl Protection-Deblocking under Ru(II)/(IV)-Catalysis.Organic letters · 2019Article
- Review
- Lysophosphatidic acid produced by autotaxin acts as an allosteric modulator of its catalytic efficiency.The Journal of biological chemistry · 2018Article
- Platelets, autotaxin and lysophosphatidic acid signalling: win-win factors for cancer metastasis.British journal of pharmacology · 2018Review
- Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders.Molecular psychiatry · 2018Article
- Autotaxin in Pathophysiology and Pulmonary Fibrosis.Frontiers in medicine · 2018Review
- Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development.Mediators of inflammation · 2017Review
- Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate.Journal of lipid research · 2015Article
- Lysophosphatidic acid mediates fibrosis in injured joints by regulating collagen type I biosynthesis.Osteoarthritis and cartilage · 2015Article
- Article
- Autotaxin and Endotoxin-Induced Acute Lung Injury.PloS one · 2015Article
- Promising pharmacological directions in the world of lysophosphatidic Acid signaling.Biomolecules & therapeutics · 2015Review
- LPA receptor signaling: pharmacology, physiology, and pathophysiology.Journal of lipid research · 2014Review
- The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation.Journal of immunology (Baltimore, Md. : 1950) · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a destructive arthropathy with systemic manifestations, characterized by chronic synovial inflammation. Under the influence of the pro-inflammatory milieu synovial fibroblasts (SFs), the main effector cells in disease pathogenesis become activated and hyperplastic while releasing a number of signals that include pro-inflammatory factors and tissue remodeling enzymes. Activated RA SFs in mouse or human arthritic joints express significant quantities of autotaxin (ATX), a lysophospholipase D responsible for the majority of lysophosphatidic acid (LPA) production in the serum and inflamed sites. Conditional genetic ablation of ATX from SFs resulted in attenuation of disease symptoms in animal models, an effect attributed to diminished LPA signaling in the synovium, shown to activate SF effector functions. Here we show that administration of 1-bromo-3(S)-hydroxy-4-(palmitoyloxy)butyl-phosphonate (BrP-LPA), a metabolically stabilized analog of LPA and a dual function inhibitor of ATX and pan-antagonist of LPA receptors, attenuates collagen induced arthritis (CIA) development, thus validating the ATX/LPA axis as a novel therapeutic target in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.